Applications of stable isotopes in clinical pharmacology

Authors

  • Reinout C. A. Schellekens,

    Corresponding author
    1. Departments of Hospital and Clinical Pharmacy
    2. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
      Dr Reinout C. A. Schellekens, Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. Tel.: +31 50 361 4071, Fax: +31 50 361 4087, E-mail: reinout.schellekens@kpnplanet.nl
    Search for more papers by this author
  • Frans Stellaard,

    1. Laboratory Medicine, University Medical Center Groningen, The Netherlands
    Search for more papers by this author
  • Herman J. Woerdenbag,

    1. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
    Search for more papers by this author
  • Henderik W. Frijlink,

    1. Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
    Search for more papers by this author
  • Jos G. W. Kosterink

    1. Departments of Hospital and Clinical Pharmacy
    Search for more papers by this author

Errata

This article is corrected by:

  1. Errata: Erratum Volume 75, Issue 4, 1171, Article first published online: 15 March 2013

Dr Reinout C. A. Schellekens, Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. Tel.: +31 50 361 4071, Fax: +31 50 361 4087, E-mail: reinout.schellekens@kpnplanet.nl

Abstract

This review aims to present an overview of the application of stable isotope technology in clinical pharmacology. Three main categories of stable isotope technology can be distinguished in clinical pharmacology. Firstly, it is applied in the assessment of drug pharmacology to determine the pharmacokinetic profile or mode of action of a drug substance. Secondly, stable isotopes may be used for the assessment of drug products or drug delivery systems by determination of parameters such as the bioavailability or the release profile. Thirdly, patients may be assessed in relation to patient-specific drug treatment; this concept is often called personalized medicine. In this article, the application of stable isotope technology in the aforementioned three areas is reviewed, with emphasis on developments over the past 25 years. The applications are illustrated with examples from clinical studies in humans.

Ancillary